ANUHPHR · Health Care · 2026-08-21

Anuh Pharma Ltd

3.3WatchWeak -0.2Stage 2 · wk 2In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹76
+0.16% today
₹762 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.

Visit company website →
P/E (TTM)
18.3
Forward —
Earnings Growth (YoY)
-6.0%
Revenue +2.0%
ROE
+12.1%
Profit margin +5.3%
Dividend Yield
1.96%
P/B 2.2
vs 52W High
-17.5%
₹67 lo₹92.1 hi
17.5% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
-3.2%
200 DMA: ₹78.5 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.47x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -2.0% vs MA50 +0.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #77 of 84 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #53 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2024-12-20 → 2026-08-21
S? 42w
S4 28w
S1 12w
2024-12-202026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 28w → S1 12w → S4 3w → S2 2w current
Total tracked: 87 weeks across 5 stage runs.
1M
-4.3%
3M
+0.6%
6M
-6.2%
YTD
-5.6%
1Y
-12.3%
Scan Membership
Breakout Watch
Latest: 2026-08-10
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 2 · Vol —x
2026-08-20S2
Wk 2 · Vol —x
2026-08-19S2
Wk 2 · Vol —x
2026-08-18S2
Wk 2 · Vol —x
2026-08-17S2
Wk 2 · Vol —x
2026-08-14S2
Wk 1 · Vol —x
2026-08-13S2
Wk 1 · Vol —x
2026-08-12S2
Wk 1 · Vol —x
2026-08-11S2
Wk 1 · Vol —x
2026-08-10S24→2
Wk 1 · Vol —x
2026-08-07S4
Wk 4 · Vol —x
2026-08-06S4
Wk 3 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹78.9
200 DMA
₹78.5
52W High
₹92.1
52W Low
₹67
5D Low
₹75.7
Resistance levels (recent highs)
20d High
₹80.7
60d High
₹81.5
120d High
₹85.3
250d High
₹92.1
Next resistance
+6.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.